Silexion Therapeutics Files Proxy Materials
Ticker: SLXNW · Form: DEFA14A · Filed: Jun 23, 2025 · CIK: 2022416
Sentiment: neutral
Topics: proxy-statement, corporate-governance, name-change
TL;DR
Silexion (fka Biomotion) filed proxy docs, shareholder vote incoming.
AI Summary
Silexion Therapeutics Corp filed a Definitive Additional Materials proxy statement on June 23, 2025. This filing relates to the company's proxy materials, indicating a shareholder meeting or vote is approaching. The company, formerly known as Biomotion Sciences until May 6, 2024, is involved in the biological products sector.
Why It Matters
This filing signals upcoming shareholder decisions or meetings, which could impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain information about significant financial events or strategic shifts.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- 20250623 (date) — Filing date
- 20240506 (date) — Date of name change
FAQ
What is the purpose of this DEFA14A filing?
This filing is a Definitive Additional Materials proxy statement filed by Silexion Therapeutics Corp, indicating it is providing supplementary materials related to a proxy solicitation.
When was Silexion Therapeutics Corp formerly known as?
Silexion Therapeutics Corp was formerly known as Biomotion Sciences, with the name change occurring on May 6, 2024.
What is Silexion Therapeutics Corp's Standard Industrial Classification code?
Silexion Therapeutics Corp's Standard Industrial Classification code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the filing date of this document?
The filing date of this DEFA14A document is June 23, 2025.
Where is Silexion Therapeutics Corp located?
Silexion Therapeutics Corp is located at 12 Abba Hillel Road, Ramat Gan, L3, 5250606.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 23, 2025 regarding Silexion Therapeutics Corp (SLXNW).